Reading : 1 minute

NETRIS Pharma is pleased to announce the arrival of Frédéric Le Bras, MD; as the new company Chief Medical Officer. Graduated from René Descartes University in Paris, Frédéric obtained his oncology degree from the Gustave Roussy Institute and mainly worked in pharmaceutical industries in medical affairs, in oncology, rare diseases and immunology, both in France and in Europe.

“We are very excited to welcome Frederic at NETRIS Pharma” comments Patrick Mehlen, CEO. “Frédéric has a very large experience in the pharmaceutical industry to conduct clinical trial. His timely venue will be instrumental especially when considering the upcoming combination trials that will soon start with our lead asset NP137”.

After 29 years spent in oncology and in specialty care in big pharma, Frédéric is very enthusiastic to join NETRIS Pharma: “Not only the great hope of developing a first-in-class compound bringing new hopes in cancer is an exciting challenge but bringing my expertise to a very scientific and dynamic French human-size clinical stage company in Oncology is definitively a new personal project ” says Frédéric, adding that “Oncology is like a marathon: you have to start running as fast as you can without forgetting the long way you still have to run.”

Suggested articles

logo Nature article

NETRIS Pharma announces data published in two Nature papers confirming netrin-1 blockade as significant clinical strategy in oncology

* Anti-netrin-1 monoclonal antibody, NP137, demonstrates objective response and disease stabilization as monotherapy in Phase 1 study of patients with advanced endometrial carcinoma (EC); effective in inhibiting tumor growth in several different preclinical mouse models. * Paired biopsies, pre-and-on NP137 treatment, highlight a statistically significant reduction of tumor epithelial-to-mesenchymal transition. * Netrin-1 blockade with NP137, is confirmed as a clinical strategy to alleviate resistance to standard treatments, in multiple clinical indications, including EC.

Reading : 15 min
Bio Boston 2023

NETRIS Pharma attending the Bio International Convention in Boston (June 5-8, 2023)

NETRIS Pharma, a clinical-stage immuno-oncology pharmaceutical company pioneering NETRIN-1-based drug discovery and development, is confirming today that CEO and Founder Patrick Mehlen, and CFO Christophe Guichard, will be attending the Bio International Convention taking place June 5-8, 2023, in Boston, MS. Meet with us at the Partnering booth ! For any information, please send an email to christopheguichard@netrispharma.com

Reading : 1 min

NETRIS Pharma Doses First Patient in Pancreatic Cancer Clinical Study with NP137

Lap-NET1 study will evaluate safety and efficacy of anti-netrin-1 antibody NP137 in combination with m_FOLFIRINOX for first line patients with Locally Advanced Pancreatic Ductal Adenocarcinoma

Reading : 5 min